March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Effect of Sirolimus on Proliferation and Differentiation of Human Corneal Fibroblasts
Author Affiliations & Notes
  • Behrad Y. Milani
    Ophthalmology, Univ of Illinois at Chicago, Chicago, Illinois
  • Abed Namavari
    Ophthalmology, Univ of Illinois at Chicago, Chicago, Illinois
  • Maryam A. Shafiq
    Ophthalmology, Univ of Illinois at Chicago, Chicago, Illinois
  • Mercede Majdi
    Ophthalmology, Univ of Illinois at Chicago, Chicago, Illinois
  • Asadolah Movahedan
    Ophthalmology, Univ of Illinois at Chicago, Chicago, Illinois
  • Hossein M. Sagha
    Ophthalmology, Univ of Illinois at Chicago, Chicago, Illinois
  • Ali R. Djalilian
    Ophthalmology, Univ of Illinois at Chicago, Chicago, Illinois
  • Footnotes
    Commercial Relationships  Behrad Y. Milani, None; Abed Namavari, None; Maryam A. Shafiq, None; Mercede Majdi, None; Asadolah Movahedan, None; Hossein M. Sagha, None; Ali R. Djalilian, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 1081. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Behrad Y. Milani, Abed Namavari, Maryam A. Shafiq, Mercede Majdi, Asadolah Movahedan, Hossein M. Sagha, Ali R. Djalilian; Effect of Sirolimus on Proliferation and Differentiation of Human Corneal Fibroblasts. Invest. Ophthalmol. Vis. Sci. 2012;53(14):1081.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Corneal scarring is largely due to proliferation and differentiation of corneal fibroblasts into myofibroblasts. The purpose of this study was to first examine the effects of sirolimus (an inhibitor of the mTOR pathway) on human corneal fibroblast proliferation and differentiation. Next, we wished to investigate the effect of sirolimus in preventing stromal haze formation after Photorefractive Keratectomy in a rabbit model.

Methods: : Human corneal fibroblast cultures were initiated from donated human corneal tissue. After passages 3, the fibroblasts were treated with Sirolimus (1 μg/ml) + TGF-β (1 ng/ml) or TGF-β alone as control. Cell proliferation and expression of the myofibroblast marker alpha-smooth muscle actin (αSMA) were examined by phase-contrast microscopy and immunostaining. For in vivo studies, 140 micron PTK was performed on the right eye of 12 New Zealand White rabbits. Six eyes received 1mg subconjunctival sirolimus immediately and 2 weeks following the surgery. Six eye received vehicle in the same fashion. Corneas were followed by slit-lamp microscopy and were graded for haze development weekly for 4 weeks. At one month post-surgery, the animals were euthanized and corneas were subjected to immunostaining for myofibroblast marker alpha-smooth muscle actin (αSMA), and Tunel assay for apoptosis.

Results: : Cell proliferation was significantly reduced in the Sirolimus group compared to control (6.2±1.6 vs. 33.3±5.4 cells/20x field). The percentage of SMA positive cells was significantly lower in the Sirolimus group compared to control (16.2% vs. 78.6%). Corneal haze was significantly less in the sirolimus group compared with the control group (0.75±0.4 vs. 2.17±0.7). The density of SMA+ cell/400x field in the central stroma was significantly lower in the sirolimus group compared with the control group (5.8±1.4 cells vs. 18.2±3.2 cells). Tunel assays and Clinical eye examination revealed sirolimus is nontoxic for the cornea.

Conclusions: : Sirolimus appears to inhibit proliferation and differentiation of corneal fibroblasts into myofibroblasts in vitro. Furthermore, subconjunctival sirolimus is effective for preventing corneal stromal haze formation after PTK in a rabbit model.

Keywords: cornea: stroma and keratocytes • cornea: basic science • refractive surgery: complications 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×